Who are CYP2C19 genotype guided P2Y12 monotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel, cilostazol, Clopidogrel only, aspirin + clopidogrel + celecoxib, prasugrel/bivalirudin, Clopidogrel active metabolite, Clopidogrel reloading.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyp2c19-genotype-guided-p2y12-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CYP2C19 genotype guided P2Y12 monotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CYP2C19 genotype guided P2Y12 monotherapy (CYP2C19 genotype guided P2Y12 monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 inhibitor (antiplatelet agent). Area: Cardiovascular.

marketed P2Y12 inhibitor (antiplatelet agent) P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

CYP2C19 genotype guided P2Y12 monotherapy (CYP2C19 genotype guided P2Y12 monotherapy) — St. Antonius Hospital. CYP2C19 genotype-guided P2Y12 monotherapy uses genetic testing to select appropriate P2Y12 inhibitor dosing or choice based on individual cytochrome P450 2C19 metabolizer status, optimizing antiplatelet efficacy while reducing bleeding risk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CYP2C19 genotype guided P2Y12 monotherapy TARGET	CYP2C19 genotype guided P2Y12 monotherapy	St. Antonius Hospital	marketed	P2Y12 inhibitor (antiplatelet agent)	P2Y12 receptor
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
Clopidogrel only	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
prasugrel/bivalirudin	prasugrel/bivalirudin	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Antiplatelet agent + Direct thrombin inhibitor combination	P2Y12 receptor (prasugrel); Thrombin (bivalirudin)
Clopidogrel active metabolite	Clopidogrel active metabolite	University of Florida	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 inhibitor (antiplatelet agent) class)

St. Antonius Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CYP2C19 genotype guided P2Y12 monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/cyp2c19-genotype-guided-p2y12-monotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab